Skip to main content

Patou Gary's Form 4/A amendment

Amended

Xenon Pharmaceuticals Inc.XENE · filed Dec 15, 2023

Accession no.
0000950170-23-070912
Filed
Dec 15, 2023
Trade date
Dec 14, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not checked
Original filed
Dec 15, 2023

This filing lists 1 non-derivative transaction. It carries over 12 transactions from the original filing that it did not restate. Open-market sales total $759.0K. It was filed 1 day after the trade.

This amendment restates part of 0000950170-23-070841 (filed Dec 15, 2023). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Patou GaryCIK 0001283535Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 14, 2023Common SharesSSaleDisposed−7,598$41.05F2−$311,897.94,902Indirect

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0000950170-23-070841 (filed Dec 15, 2023).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0000950170-23-070841
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 13, 2023Common SharesMOption exerciseAcquired+6,378$9.85F2+$62,823.329,951Direct
Dec 13, 2023Common SharesFTax withholdingDisposed−1,278$39.68F3−$50,711.0428,673Direct
Dec 13, 2023Common SharesSSaleDisposed−5,100$38.94F4−$198,59423,573Direct
Dec 13, 2023Common SharesMOption exerciseAcquired+2,880$9.85F2+$28,36826,453Direct
Dec 13, 2023Common SharesFTax withholdingDisposed−577$39.68F3−$22,895.3625,876Direct
Dec 13, 2023Common SharesSSaleDisposed−2,303$39.10F5−$90,047.323,573Direct
Dec 13, 2023Common SharesMOption exerciseAcquired+5,144$9.00+$46,29628,717Direct
Dec 13, 2023Common SharesFTax withholdingDisposed−1,167$39.68F3−$46,306.5627,550Direct
Dec 13, 2023Common SharesSSaleDisposed−3,977$39.84−$158,443.6823,573Direct

Derivative securities (Table II)

Derivative transactions carried over from 0000950170-23-070841
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 13, 2023Common SharesMOption exerciseDisposed−6,378$0.00$00Direct
Dec 13, 2023Common SharesMOption exerciseDisposed−2,800$0.00$00Direct
Dec 13, 2023Common SharesMOption exerciseDisposed−5,144$0.00$00Direct

Footnotes on the original

The footnotes that the prices of these transactions refer to on the original filing.

F2

The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Referenced by the price of 2 transactions in Table I.

F3

Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Referenced by the price of 3 transactions in Table I.

F4

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F5

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F2

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F3

By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.

Remarks

This amendment corrects the transaction date that was inaccurately reported on the original Form 4 due to a clerical error.

Read the full filing on SEC EDGAR (opens in a new tab)